| SC 13G/A | 2024-02-14 | LYTTON LAURENCE W | TFF Pharmaceuticals, Inc. | 11,900 | 0.1% | EDGAR |
| SC 13G/A | 2023-02-14 | Lung Therapeutics, Inc. | TFF Pharmaceuticals, Inc. | 773,000 | 2.1% | EDGAR |
| SC 13G/A | 2023-02-13 | LYTTON LAURENCE W | TFF Pharmaceuticals, Inc. | 3,125,722 | 8.4% | EDGAR |
| SC 13G/A | 2023-02-09 | CARLSON CAPITAL L P | TFF Pharmaceuticals, Inc. | 1,842,000 | 5.1% | EDGAR |
| SC 13G | 2022-11-28 | CARLSON CAPITAL L P | TFF Pharmaceuticals, Inc. | 2,194,000 | 6.2% | EDGAR |
| SC 13G | 2022-11-23 | LYTTON LAURENCE W | TFF Pharmaceuticals, Inc. | 3,137,641 | 8.8% | EDGAR |
| SC 13G/A | 2022-02-14 | Nantahala Capital Management, LLC | TFF Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Corriente Advisors, LLC | TFF Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Lung Therapeutics, Inc. | TFF Pharmaceuticals, Inc. | 2,235,000 | 8.8% | EDGAR |
| SC 13G | 2021-02-16 | Nantahala Capital Management, LLC | TFF Pharmaceuticals, Inc. | 1,763,476 | 7.9% | EDGAR |
| SC 13G | 2021-02-16 | Corriente Advisors, LLC | TFF Pharmaceuticals, Inc. | 1,350,000 | 6.1% | EDGAR |
| SC 13G/A | 2021-02-03 | Lung Therapeutics, Inc. | TFF Pharmaceuticals, Inc. | 2,950,000 | 13.3% | EDGAR |
| SC 13G | 2020-02-03 | Lung Therapeutics, Inc. | TFF Pharmaceuticals, Inc. | 4,000,000 | 21.7% | EDGAR |